Brian Cain

Incanthera Plc operates as a holding company, which focuses on drug discovery and development of targeted medicines for the treatment of cancer. The firm products include Sol, EP0015, Equin & Duo-C. The company was founded on March 2, 2010 and is headquartered in Manchester, the United Kingdom.

Incanthera Oncology Ltd. engages in the provision of drug development services. The company was founded on April 7, 2011 and is headquartered in Manchester, the United kingdom.

Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom.

Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell.

CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb.

Deuterx LLC engages in research of biotechnology. It also engages in development of biotechnology. The company was founded by Anthony W. Czarnik in 2012 and is headquartered in Andover, MA.

Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA.

Tyrogenex, Inc. operates as a biopharmaceutical company which develops dual vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitors for wet age-related macular degeneration and solid tumors. Its compound targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation. The company was founded by Chris Liang, Teri Ardleigh Swift, and Sheridan G. Snyder and is headquartered in Rockville, MD.

Allegro Diagnostics Corp. develops and commercializes molecular diagnostics system. It focuses on lung cancer and other pulmonary diseases using proprietary gene expression technology originating within the Pulmonary Center at the Boston University School of Medicine. The company was founded by Jerome S. Brody and Avrum Spira on April 20, 2007 and is headquartered in Maynard, MA.

CEO Roundtable on Cancer, Inc. promotes activities to reduce cancer risk, enable early detection, facilitate better access to treatment and hasten the discovery. Its programs include CEO cancer gold standard, life sciences consortium and project data sphere. The company was founded by George H. W. Bush in 2001 and is headquartered in Durham, NC.

Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann.